SCHEMBL8533987

SCHEMBL8533987

CCc1cnc(N2CCC(Oc3ccc(-n4ccc5cc(NC(=O)C(C)C)ccc54)nc3)CC2)nc1

nearest known ligand 0.46

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 8/20 0.46
CHRNA7 P36544 2/20 0.44
ACACB O00763 10/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8536451 0.92 CHRNA7 (0.48) GPR119CHRNA7ACACB
SCHEMBL9265925 0.91 GPR119 (0.44) GPR119CHRNA7ACACB
SCHEMBL8533540 0.91 GPR119 (0.45) GPR119ACACB
SCHEMBL9254261 0.89 CHRNA7 (0.48) GPR119CHRNA7ACACB
SCHEMBL15253290 0.89 GPR119 (0.58) GPR119CHRNA7ACACB
SCHEMBL8531649 0.89 ACACB (0.45) GPR119CHRNA7ACACB
SCHEMBL8533577 0.85 PLK1 (0.46) GPR119ACACB
SCHEMBL8537175 0.85 GPR119 (0.47) GPR119ACACB
SCHEMBL8533375 0.85 CHRNA7 (0.47) GPR119CHRNA7ACACB
SCHEMBL8532561 0.84 GPR119 (0.44) GPR119ACACB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9000175-B2 Bicyclic GPR119 modulators LUPIN LIMITED (IN) 2015-04-07 US claimed
US-20130245000-A1 BICYCLIC GPR119 MODULATORS LUPIN LIMITED (IN) 2013-09-19 US claimed
US-9000175-B2 Bicyclic GPR119 modulators LUPIN LIMITED (IN) 2015-04-07 US disclosed
US-9000175-B2 Bicyclic GPR119 modulators LUPIN LIMITED (IN) 2015-04-07 US disclosed
EP-2643311-A1 BICYCLIC GPR119 MODULATORS Lupin Limited (IN) 2013-10-02 EP disclosed
US-20130245000-A1 BICYCLIC GPR119 MODULATORS LUPIN LIMITED (IN) 2013-09-19 US disclosed
US-20130245000-A1 BICYCLIC GPR119 MODULATORS LUPIN LIMITED (IN) 2013-09-19 US disclosed
WO-2012069917-A1 BICYCLIC GPR119 MODULATORS LUPIN LIMITED (IN) 2012-05-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130245000-A1 BICYCLIC GPR119 MODULATORS GPR119, GPR180, GPBAR1 GPR119 1/4885CHRNA7 497/4885ACACB 882/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.